[Double-blind comparative study of slow-release ketoprofen and a placebo in chronic inflammatory rheumatism].
Twenty-five inpatients with chronic inflammatory rheumatic disease were entered into a double blind crossover trial. Consecutive treatment regimens consisted of a single daily dose of Bi-Profenid 150 mg at 8 pm for 3 days and a single placebo tablet at 8 pm for 3 days. Order of treatment regimens was randomly assigned. Bi-Profenid proved highly superior to placebo with a very significant (p less than 0.01) difference in effectiveness on nocturnal pain, morning stiffness and pain evaluated on the pain scale. During the short treatment period no significant clinical side-effects were recorded. The authors conclude that Bi-Profenid is effective at a daily dosage of 150 mg, thus enabling to adjust prescriptions to actual needs when pain is not continuous throughout the 24 hours.
D000328:Adult; D000368:Aged; D001168:Arthritis / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007660:Ketoprofen / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000008:administration & dosage*; D010919:Placebos
D003692:Delayed-Action Preparations; D010666:Phenylpropionates; D010919:Placebos; D007660:Ketoprofen
Etude comparative á double insu du kétoprofène à libération prolongée et d'un placebo dans les rhumatismes inflammatoires chroniques.